CT Private Equity Trust (LON:CTPE) Shares Up 0.4% - Still a Buy?

Key Points

• CT Private Equity Trust (LON:CTPE) shares rose by 0.4% on Friday, closing at GBX 474 ($6.33), with a trading volume increase of 3% from the average.
• The company reported £338.92 million market cap, a price-to-earnings ratio of 6,076.92, and a net margin of 59.97%.
• CT Private Equity Trust specializes in investing in high-quality smaller and mid-sized private companies, aiming for strong growth through a diversified strategy involving over 500 companies.

CT Private Equity Trust PLC (LON:CTPE - Get Free Report) shares shot up 0.4% during mid-day trading on Friday . The company traded as high as GBX 474 ($6.33) and last traded at GBX 474 ($6.33). 90,847 shares changed hands during trading, an increase of 3% from the average session volume of 87,893 shares. The stock had previously closed at GBX 472 ($6.30).

CT Private Equity Trust Stock Up 0.4%

The stock has a market cap of £338.92 million, a price-to-earnings ratio of 6,076.92 and a beta of 0.75. The business has a 50-day moving average of GBX 470.73 and a 200-day moving average of GBX 471.88.

CT Private Equity Trust (LON:CTPE - Get Free Report) last released its quarterly earnings data on Thursday, August 28th. The company reported GBX 1.36 earnings per share (EPS) for the quarter. CT Private Equity Trust had a return on equity of 1.10% and a net margin of 59.97%.

CT Private Equity Trust Company Profile

We invest in high-quality smaller and mid-sized private companies selected by experienced Private Equity managers, mainly across the UK and Europe, that typically demonstrate strong growth, profitability, and sound management. Our diversified strategy means that we are invested in over 500 companies with 50 carefully selected PE managers, reducing risk and helping us find the best small and mid-size growth companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.